| Literature DB >> 29582633 |
Nadine M Hamieh1, Reem Akel, Bilal Anouti, Cindy Traboulsi, Iman Makki, Lana Hamieh, Arafat Tfayli.
Abstract
Background: Despite pain awareness and the development of treatment guidelines, cancer-related pain assessment and management remain suboptimal. Our objectives were to estimate the prevalence and severity of pain and its interference with daily activities, and evaluate adequacy of treatment in cancer patients in Lebanon.Entities:
Keywords: Pain; cancer; prevalence; severity; Lebanon
Mesh:
Year: 2018 PMID: 29582633 PMCID: PMC5980854 DOI: 10.22034/APJCP.2018.19.3.769
Source DB: PubMed Journal: Asian Pac J Cancer Prev ISSN: 1513-7368
Demographic and Clinical Characteristics of 400 Cancer Patients at AUBMC
| Total N=400 | Patients with pain N=119 | Patients without pain N=281 | P | |
|---|---|---|---|---|
| Demographic characteristics | ||||
| Mean (SD) age, years | 54.7 (14.4) | 53.3 (14.2) | 55.3 (14.5) | 0.23☐ |
| Female, % | 62.7 | 74.8 | 57.7 | 0.001*§ |
| Married, % | 80.2 | 77.1 | 81.5 | 0.39 § |
| Education (university level/below university level), % | 48.5/51.5 | 48.6/51.4 | 48.4/51.6 | 1.00 § |
| Living in urban areas, % | 85.8 | 79.8 | 88.3 | 0.03* § |
| Insured, % | 81.3 | 75.2 | 83.8 | 0.06 § |
| Nationality (Lebanese/ Iraqi/other), % | 76.0/12.3/3.8 | 70.6/18.5/2.5 | 78.3/9.6/4.3 | 0.04* · |
| Religion (Christian/Muslim/unknown), % | 19.8/64.2/16.0 | 15.1/62.2/22.7 | 21.7/65.1/13.2 | 0.30 § |
| Clinical characteristics | ||||
| Cancer site, % | ||||
| Breast | 38.8 | 48.7 | 34.5 | 0.01*§ |
| Lung | 4.5 | 3.4 | 5 | |
| Colon | 12.3 | 5 | 15.3 | |
| Non-colon gastrointestinal | 11.5 | 14.3 | 10.3 | |
| Hematologic | 17.3 | 14.3 | 18.5 | |
| Other | 15.6 | 14.3 | 16.4 | |
| Cancer stage, % | ||||
| Stage I | 4 | 5.9 | 3.2 | 0.13· |
| Stage II | 16 | 18.5 | 14.9 | |
| Stage III | 15.3 | 18.5 | 14 | |
| Stage IV | 52.7 | 44.5 | 56.2 | |
| Not applicable (e.g. hematologic) | 12 | 12.6 | 11.7 | |
| Type of treatment, % | ||||
| Surgery | 1.4 | 2.8 | 0.8 | 0.22 · |
| Systemic therapy | 43.5 | 45.9 | 42.5 | |
| Surgery and systemic therapy | 55.1 | 51.4 | 56.7 |
*, pvalue≤0.05; ·, Fisher’s exact test; §, Chi-square test; ☐, Independent t-test
Characteristics of 119 Cancer Patients with History of Pain at AUBMC
| N=119 | |
|---|---|
| Mean (SD) duration of pain, weeks | 2.9 (1.3) |
| Duration of pain, Median | 4 |
| Adherence to prescribed pain medications, % | |
| Yes | 78.2 |
| No | 1.7 |
| No need for medications | 20.1 |
| Pain improvement | |
| Yes | 67.9 |
| Mildly | 13.3 |
| Moderately | 48 |
| Completely | 38.7 |
| No | 32.1 |
| Pain severity in the past 24 hours, % | |
| No pain | 26.1 |
| Mild pain | 31.9 |
| Moderate pain | 37.8 |
| Severe pain | 4.2 |
| Analgesics used, % | |
| Non-opioid | 61.8 |
| Weak opioid | 32.9 |
| Strong opioid | 5.3 |
| Pain Management Index, % | |
| Adequate treatment | 44.5 |
| Inadequate treatment | 55.5 |
| Location of pain | |
| Head | 16.8 |
| Back | 23.5 |
| Extremities | 40.3 |
| Trunk | 30.3 |
| Other | 5 |
Percentages do not add to a hundred since every participant chose more than one pain site
Pearson’s Correlation Coefficients of Pain Interference and Pain Severity
| Variables | Pain interference | |||||||
|---|---|---|---|---|---|---|---|---|
| Total | General activity | Mood | Walking activity | Normal work | Relation with other people | Sleep | Enjoyment of life | |
| Total pain severity | 0.16 | 0.15 | -0.01 | 0.13 | 0.15 | 0.08 | 0.15 | 0.11 |
| Least pain | 0.16 | 0.42 | 0.33 | 0.28 | 0.29 | 0.35 | 0.45 | 0.50 |
| Average pain | 0.19 | 0.14 | 0.16 | 0.11 | 0.17 | 0.23 | 0.13 | 0.31 |
| Worst pain | 0.28 | 0.58 | 0.60 | 0.45 | 0.51 | 0.46 | 0.58 | 0.62 |
pvalue≤0.05
Risk Factors for Pain in Cancer Patients at AUBMC
| Unadjusted OR (95%CI) | P | Adjusted OR (95% CI) | P | |
|---|---|---|---|---|
| Age | 0.99 (0.98-1.01) | 0.23 | 0.99 (0.98-1.01) | 0.56 |
| Gender | ||||
| Male | 1.00 | 0.001 | 1.00 | 0.03 |
| Female | 2.18 (1.35-3.51) | 1.97 (1.07-3.62) | ||
| Type of residency | ||||
| Urban | 1.00 | 0.03 | 1.00 | 0.04 |
| Rural | 1.90 (1.07-3.38) | 1.89 (1.04-3.44) | ||
| Cancer site | ||||
| Breast | 1.00 | 0.02 | 1.00 | 0.10 |
| Lungs | 0.48 (0.15-1.52) | 0.21 | 0.78 (0.23-2.71) | 0.7 |
| Colon | 0.23 (0.09-0.58) | 0.002 | 0.36 (0.14-0.94) | 0.04 |
| Non-colon gastrointestinal | 0.55 (0.29-1.03) | 0.06 | 0.77 (0.38-1.57) | 0.47 |
| Hematology | 0.98 (0.50-1.94) | 0.96 | 1.71 (0.76-3.84) | 0.2 |
| Other | 0.62 (0.32-1.18) | 0.14 | 0.89 (0.43-1.83) | 0.75 |
| Education | ||||
| Below university level | 1.00 | 0.94 | ||
| University level | 0.98 (0.62-1.55) | |||
| Cancer stage | ||||
| Stage I | 1.00 | 0.14 | ||
| Stage II | 0.67 (0.22-2.05) | 0.49 | ||
| Stage III | 0.73 (0.24-2.22) | 0.57 | ||
| Stage IV | 0.43 (0.15-1.22) | 0.11 | ||
| Type of treatment | ||||
| Surgery | 1.00 | 0.28 | ||
| Systemic therapy | 0.30 (0.05-1.85) | 0.20 | ||
| Surgery + systemic therapy | 0.25 (0.04-1.55) | 0.14 |
pvalue≤0.05